{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T06:22:08Z","timestamp":1787552528293,"version":"build-2736575974"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"DOI":"10.1007\/s11912-026-01816-0","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T06:09:05Z","timestamp":1787551745000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Minimal Residual Disease in Head and Neck Cancer: Molecular Surveillance and Clinical Action"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0651-6994","authenticated-orcid":false,"given":"Sholem","family":"Hack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eran E.","family":"Alon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Remer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"1816_CR1","doi-asserted-by":"publisher","unstructured":"Liu Y, Zhang N, Wen Y, Wen J. Head and neck cancer: pathogenesis and targeted therapy. MedComm (Beijing) [Internet]. John Wiley & Sons, Ltd; 2024 [cited 2025 Sep 28];5:e702. https:\/\/doi.org\/10.1002\/MCO2.702.","DOI":"10.1002\/MCO2.702"},{"key":"1816_CR2","doi-asserted-by":"publisher","unstructured":"Aboaid H, Khalid T, Hussain A, Myat YM, Nanda RK, Srinivasmurthy R, et al. Advances and challenges in immunotherapy in head and neck cancer. Front Immunol [Internet]. Front Immunol; 2025 [cited 2025 Sep 28];16. https:\/\/doi.org\/10.3389\/FIMMU.2025.1596583.","DOI":"10.3389\/FIMMU.2025.1596583"},{"key":"1816_CR3","doi-asserted-by":"publisher","first-page":"658","DOI":"10.21873\/CDP.10378","volume":"4","author":"M Matsuo","year":"2024","unstructured":"Matsuo M, Hashimoto K, Kogo R, Sato M, Manako T, Nakagawa T. Interval to recurrence affects survival in recurrent head and neck squamous cell carcinoma. Cancer diagnosis and prognosis. Int Inst Anticancer Res. 2024;4:658\u201366. https:\/\/doi.org\/10.21873\/CDP.10378.","journal-title":"Int Inst Anticancer Res"},{"key":"1816_CR4","doi-asserted-by":"publisher","unstructured":"Chen AM, Harris JP, Gan M, Nabar R, Tjoa T, Haidar YM, et al. Posttreatment surveillance imaging after radiation for head and neck cancer. JAMA Netw Open [Internet]. Am Med Assoc; 2023 [cited 2025 Sep 28];6:e2342825\u2013e2342825. https:\/\/doi.org\/10.1001\/JAMANETWORKOPEN.2023.42825","DOI":"10.1001\/JAMANETWORKOPEN.2023.42825"},{"key":"1816_CR5","doi-asserted-by":"publisher","first-page":"106354","DOI":"10.1016\/J.ORALONCOLOGY.2023.106354","volume":"139","author":"SB Mali","year":"2023","unstructured":"Mali SB. Surveillance of head neck cancer: case for personalized and standardized surveillance. Oral Oncol Pergamon. 2023;139:106354. https:\/\/doi.org\/10.1016\/J.ORALONCOLOGY.2023.106354.","journal-title":"Oral Oncol Pergamon"},{"key":"1816_CR6","doi-asserted-by":"publisher","unstructured":"Hanna GJ, Patel N, Tedla SG, Baugnon KL, Aiken A, Agrawal N. Personalizing Surveillance in Head and Neck Cancer. Am Soc Clin Oncol Educ Book [Internet]. Wolters Kluwer Health; 2023 [cited 2025 Sep 28]; https:\/\/doi.org\/10.1200\/EDBK_389718.","DOI":"10.1200\/EDBK_389718"},{"key":"1816_CR7","doi-asserted-by":"publisher","unstructured":"Hirayama S, Al-Inaya Y, Aye L, Bryan ME, Das D, Mendel J, et al. Prospective validation of ctHPVDNA for detection of minimal residual disease and prediction of recurrence in patients with HPV-associated head and neck cancer treated with surgery. J Clin Oncol [Internet]. American Society of Clinical Oncology; 2024 [cited 2025 Sep 28];42:6010\u20136010. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_SUPPL.6010.","DOI":"10.1200\/JCO.2024.42.16_SUPPL.6010"},{"key":"1816_CR8","doi-asserted-by":"publisher","unstructured":"Sim ES, Rhoades J, Xiong K, Walsh L, Crnjac A, Blewett T, et al. Early postoperative minimal residual disease detection with MAESTRO is associated with recurrence and worse survival in patients with head and neck cancer. Clin Cancer Res [Internet]. Clin Cancer Res; 2025 [cited 2025 Sep 27];31:OF1\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-0307.","DOI":"10.1158\/1078-0432.CCR-25-0307"},{"key":"1816_CR9","doi-asserted-by":"publisher","unstructured":"Chaudhuri AA, Gu Z, Whitfield D, Earland N, Harmon A, Long M, et al. Detection of minimal residual disease in post-surgical drain fluid synergizes with pathology to predict recurrence in HPV-negative head and neck cancer patients. Int J Radiat Oncol*Biology*Phys. Elsevier; 2024;118:e70. https:\/\/doi.org\/10.1016\/J.IJROBP.2024.01.156.","DOI":"10.1016\/J.IJROBP.2024.01.156"},{"key":"1816_CR10","doi-asserted-by":"publisher","unstructured":"Jones O, Bola S, Winter SC. ctDNA to predict treatment response in head and neck squamous cell carcinoma: a systematic review. Laryngoscope [Internet]. John Wiley & Sons, Ltd; 2025 [cited 2025 Sep 27];0:1\u201313. https:\/\/doi.org\/10.1002\/LARY.32440.","DOI":"10.1002\/LARY.32440"},{"key":"1816_CR11","doi-asserted-by":"publisher","unstructured":"Huang X, Duijf PHG, Sriram S, Perera G, Vasani S, Kenny L, et al. Circulating tumour DNA alterations: emerging biomarker in head and neck squamous cell carcinoma. J Biomed Sci [Internet]. BioMed Central Ltd; 2023 [cited 2025 Sep 28];30:65. https:\/\/doi.org\/10.1186\/S12929-023-00953-Z.","DOI":"10.1186\/S12929-023-00953-Z"},{"key":"1816_CR12","doi-asserted-by":"publisher","unstructured":"Yang R, Li T, Zhang S, Shui C, Ma H, Li C. The effect of circulating tumor DNA on the prognosis of patients with head and neck squamous cell carcinoma: a systematic review and meta-analysis. BMC Cancer [Internet]. BioMed Central Ltd; 2024 [cited 2025 Sep 28];24:1434. https:\/\/doi.org\/10.1186\/S12885-024-13116-6.","DOI":"10.1186\/S12885-024-13116-6"},{"key":"1816_CR13","doi-asserted-by":"crossref","unstructured":"Hanna GJ, Dennis MJ, Scarfo N, Mullin MS, Sethi RKV, Sehgal K, et al. Personalized ctDNA for monitoring disease status in head and neck squamous cell carcinoma. Clin Cancer Res [Internet]. American Association for Cancer Research Inc.; 2024 [cited 2026 Apr 14];30:3329\u201336.","DOI":"10.1158\/1078-0432.CCR-24-0590"},{"key":"1816_CR14","doi-asserted-by":"publisher","unstructured":"Flach S, Pipinikas C, Huberty T, Lechner A, Murray C, Marsico G, et al. Personalized ctDNA analysis for detection of residual disease and recurrence in surgically treated HNSCC patients. npj Precis Oncol [Internet]. Nature Publishing Group; 2026 [cited 2026 Apr 14];10(1):103-. https:\/\/doi.org\/10.1038\/s41698-026-01309-0.","DOI":"10.1038\/s41698-026-01309-0"},{"key":"1816_CR15","doi-asserted-by":"publisher","unstructured":"Sanz-Garcia E, Zou J, Avery L, Spreafico A, Waldron J, Goldstein D, et al. Multimodal detection of molecular residual disease in high-risk locally advanced squamous cell carcinoma of the head and neck. Cell Death Differ [Internet]. Nature Publishing Group; 2024 [cited 2025 Sep 27];31(4):460\u20138. https:\/\/doi.org\/10.1038\/s41418-024-01272-y.","DOI":"10.1038\/s41418-024-01272-y"},{"key":"1816_CR16","doi-asserted-by":"publisher","unstructured":"Honor\u00e9 N, Laliotis G, Aushev V, Velichko S, Palsuledesai C, Dahou H, et al. Tumor-informed ctDNA assay to predict recurrence in locally advanced squamous-cell carcinoma of the head and neck (SCCHN). ESMO Open [Internet]. Elsevier B.V.; 2025 [cited 2026 Apr 14];10:104534. https:\/\/doi.org\/10.1016\/j.esmoop.2025.104534.","DOI":"10.1016\/j.esmoop.2025.104534"},{"key":"1816_CR17","doi-asserted-by":"publisher","unstructured":"Lam WKJ, Kang G, Chan CML, Lee VCT, Ma MJL, Zhou Q, et al. Fragmentomics profiling and quantification of plasma Epstein-Barr virus DNA enhance prediction of future nasopharyngeal carcinoma. Cancer Cell [Internet]. Cancer Cell; 2025 [cited 2025 Sep 28];43:728\u2013739.e5. https:\/\/doi.org\/10.1016\/J.CCELL.2025.02.002.","DOI":"10.1016\/J.CCELL.2025.02.002"},{"key":"1816_CR18","doi-asserted-by":"publisher","unstructured":"Ferrandino RM, Barlow J, Gold B, Kraft D, Roof SA, Teng MS, et al. Diagnostic accuracy of circulating tumor HPV DNA testing in patients with a lateral neck mass. JAMA Otolaryngol Head Neck Surg [Internet]. JAMA Otolaryngol Head Neck Surg; 2024 [cited 2025 Sep 27];150. https:\/\/doi.org\/10.1001\/JAMAOTO.2024.2702.","DOI":"10.1001\/JAMAOTO.2024.2702"},{"key":"1816_CR19","doi-asserted-by":"publisher","unstructured":"Chera BS, Kumar S, Shen C, Amdur R, Dagan R, Green R, et al. Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer. J Clin Oncol [Internet]. J Clin Oncol; 2020 [cited 2025 Sep 27];38:1050\u20138. https:\/\/doi.org\/10.1200\/JCO.19.02444.","DOI":"10.1200\/JCO.19.02444"},{"key":"1816_CR20","doi-asserted-by":"publisher","unstructured":"Farsi S, Gardner JR, King D, Sunde J, Moreno M, Vural E. Head and neck cancer surveillance: The value of computed tomography and clinical exam. Am J Otolaryngol. W.B. Saunders; 2024;45:104469. https:\/\/doi.org\/10.1016\/J.AMJOTO.2024.104469.","DOI":"10.1016\/J.AMJOTO.2024.104469"},{"key":"1816_CR21","doi-asserted-by":"crossref","unstructured":"Van Hoe S, Hermans R. Post-treatment surveillance imaging in head and neck cancer: a systematic review. Insights Imaging [Internet]. Springer Science and Business Media Deutschland GmbH; 2024 [cited 2026 Apr 14];15:32-.","DOI":"10.1186\/s13244-023-01578-4"},{"key":"1816_CR22","doi-asserted-by":"publisher","unstructured":"Caldarella C, De Risi M, Massaccesi M, Miccich\u00e8 F, Bussu F, Galli J, et al. Role of 18F-FDG PET\/CT in head and neck squamous cell carcinoma: Current evidence and innovative applications. Cancers [Internet]. Multidisciplinary Digital Publishing Institute; 2024 [cited 2026 Apr 14];16:1905. https:\/\/doi.org\/10.3390\/CANCERS16101905.","DOI":"10.3390\/CANCERS16101905"},{"key":"1816_CR23","doi-asserted-by":"publisher","unstructured":"Wong WL. PET-CT for staging and detection of recurrence of head and neck cancer. Semin Nucl Med. W.B. Saunders; 2021;51:13\u201325. https:\/\/doi.org\/10.1053\/J.SEMNUCLMED.2020.09.004.","DOI":"10.1053\/J.SEMNUCLMED.2020.09.004"},{"key":"1816_CR24","doi-asserted-by":"publisher","unstructured":"Clement C, Lecl\u00e8re JC, Maheo C, Le Pennec R, Le Gal G, Delcroix O, et al. Diagnostic performance of 18F-FDG PET\/CT according to delay after treatment to detect subclinical recurrence of head and neck squamous cell carcinoma. J Nucl Med [Internet]. Society of Nuclear Medicine; 2024 [cited 2026 Apr 14];65:1181\u20137. https:\/\/doi.org\/10.2967\/JNUMED.124.267391.","DOI":"10.2967\/JNUMED.124.267391"},{"key":"1816_CR25","doi-asserted-by":"crossref","unstructured":"ZhangY, Pang L. Explore and assess the utility of the routine 2-year post-treatment FDG PET\/CT scan on head and neck squamous cell carcinoma patients. Aust J Otolaryngol [Internet]. AME Publishing Company; 2024 [cited 2026 Apr 14];7.","DOI":"10.21037\/ajo-23-11"},{"key":"1816_CR26","doi-asserted-by":"crossref","unstructured":"Mah\u00e9oC, Abgral R, Cl\u00e9ment C, Malard O, Espitalier F, Ferron C et al. 3-year overall survival benefit of systematic follow-up with 18F-FDG PET\/CT in asymptomatic patients treated for head and neck squamous cell carcinoma: a multicenter study. Eur J Nucl Med Mol Imaging [Internet]. Springer; 2025 [cited 2026 Apr 14];52:2761\u201370.","DOI":"10.1007\/s00259-025-07147-9"},{"key":"1816_CR27","doi-asserted-by":"publisher","unstructured":"Haring CT, Kana LA, Dermody SM, Brummel C, McHugh JB, Casper KA, et al. Patterns of recurrence in head and neck squamous cell carcinoma to inform personalized surveillance protocols. Cancer [Internet]. John Wiley & Sons, Ltd; 2023 [cited 2026 Apr 14];129:2817\u201327. https:\/\/doi.org\/10.1002\/CNCR.34823.","DOI":"10.1002\/CNCR.34823"},{"key":"1816_CR28","doi-asserted-by":"publisher","unstructured":"Zhang X, Fang Q, Yuan J, Dai L, Luo R, Huang T, et al. Evaluation of ctDNA-guided adjuvant therapy de-escalation in head and neck squamous cell carcinoma: a comparative cohort study. Front Immunol [Internet]. Front Immunol; 2025 [cited 2025 Sep 27];16. https:\/\/doi.org\/10.3389\/FIMMU.2025.1576042.","DOI":"10.3389\/FIMMU.2025.1576042"},{"key":"1816_CR29","first-page":"2261","volume-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. New England J Med [Internet]","author":"J Tie","year":"2022","unstructured":"TieJ, Cohen JD, Lahouel K, Lo SN, Wang Y, Kosmider S, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. New England J Med [Internet]. Volume 386. Massachusetts Medical Society; 2022. pp. 2261\u201372. [cited 2026 Apr 14]."},{"key":"1816_CR30","doi-asserted-by":"publisher","unstructured":"Boukouris AE, Michaelidou K, Joosse SA, Charpidou A, Mavroudis D, Syrigos KN, et al. A comprehensive overview of minimal residual disease in the management of early-stage and locally advanced non-small cell lung cancer. npj Precis Oncol [Internet]. Nature Publishing Group; 2025 [cited 2025 Sep 27];9:1\u201310. https:\/\/doi.org\/10.1038\/s41698-025-00984-9.","DOI":"10.1038\/s41698-025-00984-9"},{"key":"1816_CR31","doi-asserted-by":"publisher","unstructured":"Panet F, Papakonstantinou A, Borrell M, Vivancos J, Vivancos A, Oliveira M. Use of ctDNA in early breast cancer: analytical validity and clinical potential. NPJ Breast Cancer [Internet]. Nature Research; 2024 [cited 2025 Sep 27];10:50. https:\/\/doi.org\/10.1038\/S41523-024-00653-3.","DOI":"10.1038\/S41523-024-00653-3"},{"key":"1816_CR32","doi-asserted-by":"publisher","unstructured":"Stejskal P, Goodarzi H, Srovnal J, Hajd\u00fach M, van \u2019t Veer LJ, Magbanua MJM. Circulating tumor nucleic acids: Biology, release mechanisms, and clinical relevance. Mol Cancer [Internet]. BioMed Central Ltd; 2023 [cited 2025 Sep 28];22:15. https:\/\/doi.org\/10.1186\/S12943-022-01710-W.","DOI":"10.1186\/S12943-022-01710-W"},{"key":"1816_CR33","doi-asserted-by":"publisher","unstructured":"S\u00e1nchez-Herrero E, Serna-Blasco R, Robado de Lope L, Gonz\u00e1lez-Rumayor V, Romero A, Provencio M. Circulating tumor DNA as a cancer biomarker: An overview of biological features and factors that may impact on ctDNA analysis. Front Oncol [Internet]. Frontiers Media S.A.; 2022 [cited 2025 Sep 28];12:943253. https:\/\/doi.org\/10.3389\/FONC.2022.943253.","DOI":"10.3389\/FONC.2022.943253"},{"key":"1816_CR34","doi-asserted-by":"publisher","unstructured":"Semenkovich NP, Szymanski JJ, Earland N, Chauhan PS, Pellini B, Chaudhuri AA. Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNA. J Immunother Cancer [Internet]. BMJ Publishing Group Ltd; 2023 [cited 2026 Apr 14];11:6284. https:\/\/doi.org\/10.1136\/JITC-2022-006284.","DOI":"10.1136\/JITC-2022-006284"},{"key":"1816_CR35","doi-asserted-by":"publisher","unstructured":"Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden M V., Liu MC, et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol [Internet]. Ann Oncol; 2020 [cited 2025 Sep 28];31:745\u201359. https:\/\/doi.org\/10.1016\/J.ANNONC.2020.02.011.","DOI":"10.1016\/J.ANNONC.2020.02.011"},{"key":"1816_CR36","doi-asserted-by":"publisher","unstructured":"Xie DX, Kut C, Quon H, Seiwert TY, D\u2019souza G, Fakhry C. Clinical uncertainties of circulating tumor DNA in human papillomavirus-related oropharyngeal squamous cell carcinoma in the absence of national comprehensive cancer network guidelines. J Clin Oncol [Internet]. Lippincott Williams and Wilkins; 2023 [cited 2025 Sep 28];41:2483\u20137. https:\/\/doi.org\/10.1200\/JCO.22.00264","DOI":"10.1200\/JCO.22.00264"},{"key":"1816_CR37","doi-asserted-by":"crossref","unstructured":"Sheth S, Walburn T, Tasoulas J, Patel S, Agarwal A, Gulley ML. Plasma circulating HPV DNA surveillance in a patient with nasopharyngeal cancer. Ear Nose Throat J [Internet]. SAGE Publications Ltd; 2024 [cited 2025 Sep 28].","DOI":"10.1177\/01455613241278756"},{"key":"1816_CR38","doi-asserted-by":"publisher","unstructured":"Earland N, Semenkovich NP, Ramirez RJ, Gerndt SP, Harris PK, Gu Z, et al. Sensitive MRD detection from lymphatic fluid after surgery in HPV-associated oropharyngeal cancer. Clin Cancer Res [Internet]. American Association for Cancer Research Inc.; 2023 [cited 2025 Sep 28];30:1409. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1789.","DOI":"10.1158\/1078-0432.CCR-23-1789"},{"key":"1816_CR39","doi-asserted-by":"publisher","unstructured":"Burgener JM, Zou J, Zhao Z, Zheng Y, Shen SY, Huang SH et alTumor-Na\u00efve multimodal profiling of circulating tumor DNA in head and neck squamous cell carcinoma. Clin Cancer Res [Internet]. American Association for Cancer Research Inc.; 2021 [cited 2026 Apr 14];27:4230\u201344. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0110.","DOI":"10.1158\/1078-0432.CCR-21-0110"},{"key":"1816_CR40","doi-asserted-by":"publisher","unstructured":"Honor\u00e9 N, van Marcke C, Galot R, Helaers R, Ambroise J, van Maanen A, et al. Tumor-agnostic plasma assay for circulating tumor DNA detects minimal residual disease and predicts outcome in locally advanced squamous cell carcinoma of the head and neck. Ann Oncol [Internet]. Elsevier Ltd; 2023 [cited 2026 Apr 14];34:1175\u201386. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.3102.","DOI":"10.1016\/j.annonc.2023.09.3102"},{"key":"1816_CR41","doi-asserted-by":"publisher","unstructured":"Marret G, Lamy C, Vacher S, Cabel L, S\u00e9n\u00e9 M, Ahmanache L, et al. Deciphering molecular relapse and intra-tumor heterogeneity in non-metastatic resectable head and neck squamous cell carcinoma using circulating tumor DNA. Oral Oncol. Pergamon; 2025;160:107111. https:\/\/doi.org\/10.1016\/J.ORALONCOLOGY.2024.107111.","DOI":"10.1016\/J.ORALONCOLOGY.2024.107111"},{"key":"1816_CR42","doi-asserted-by":"publisher","unstructured":"Berger BM, Hanna GJ, Posner MR, Genden EM, Lautersztain J, Naber SP, et al. Detection of occult recurrence using circulating tumor tissue modified viral HPV DNA among patients treated for HPV-driven oropharyngeal carcinoma. Clin Cancer Res [Internet]. American Association for Cancer Research Inc.; 2022 [cited 2026 Apr 14];28:4292\u2013301. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-0562.","DOI":"10.1158\/1078-0432.CCR-22-0562"},{"key":"1816_CR43","doi-asserted-by":"publisher","unstructured":"Hanna GJ, Roof SA, Jabalee J, Rettig EM, Ferrandino R, Chen S, et al. Negative predictive value of circulating tumor tissue modified viral (TTMV)-HPV DNA for HPV-driven oropharyngeal cancer surveillance. Clin Cancer Res [Internet]. American Association for Cancer Research Inc.; 2023 [cited 2026 Apr 14];29:4306\u201313. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1478.","DOI":"10.1158\/1078-0432.CCR-23-1478"},{"key":"1816_CR44","doi-asserted-by":"publisher","unstructured":"Stutheit-Zhao EY, Harris J, Zou J, Zhao Z, Zheng Y, Koyfman SA, et al. HPV-Seq is prognostic in p16-positive oropharyngeal cancer (OPC): Independent validation on a large prospective cohort and a secondary analysis of NRG-HN002. Int J Radiat Oncol*Biology*Phys. Elsevier; 2024;120:S122\u20133. https:\/\/doi.org\/10.1016\/J.IJROBP.2024.07.222.","DOI":"10.1016\/J.IJROBP.2024.07.222"},{"key":"1816_CR45","doi-asserted-by":"publisher","unstructured":"Lam WKJ, Lo YMD. Plasma Epstein-Barr virus DNA analysis for personalised management of nasopharyngeal carcinoma\u2014current opportunities and challenges. Ann Nasopharynx Cancer [Internet]. AME Publishing Company; 2022 [cited 2025 Oct 12];6:4\u20134. https:\/\/doi.org\/10.21037\/ANPC-21-11.","DOI":"10.21037\/ANPC-21-11"},{"key":"1816_CR46","doi-asserted-by":"publisher","unstructured":"Hu X, Ding SC, Jiang P. Emerging frontiers of cell-free DNA fragmentomics. Extracell Vesicles Circ Nucleic Acids 2022;3:380\u201392 [Internet]. OAE Publishing Inc.; 2022 [cited 2025 Oct 12];3:380\u201392. https:\/\/doi.org\/10.20517\/EVCNA.2022.34.","DOI":"10.20517\/EVCNA.2022.34"},{"key":"1816_CR47","doi-asserted-by":"publisher","unstructured":"Wong J, Muralidhar R, Wang L, Huang CC. Epigenetic modifications of cfDNA in liquid biopsy for the cancer care continuum. Biomed J. Elsevier; 2025;48:100718. https:\/\/doi.org\/10.1016\/J.BJ.2024.100718.","DOI":"10.1016\/J.BJ.2024.100718"},{"key":"1816_CR48","doi-asserted-by":"publisher","unstructured":"Dong W, Lau CH, Li J, Huang Z, Li J, Wu W, et al. Pan-cancer methylation analysis of circulating cell-free DNA. Cancer Genet [Internet]. Cancer Genet; 2025 [cited 2025 Oct 12];296\u2013297:182\u201395. https:\/\/doi.org\/10.1016\/J.CANCERGEN.2025.07.014.","DOI":"10.1016\/J.CANCERGEN.2025.07.014"},{"key":"1816_CR49","doi-asserted-by":"publisher","unstructured":"Liu Y. At the dawn: cell-free DNA fragmentomics and gene regulation. British J Cancer [Internet]. Nature Publishing Group; 2021 [cited 2025 Oct 12];126(3):379\u201390. https:\/\/doi.org\/10.1038\/s41416-021-01635-z.","DOI":"10.1038\/s41416-021-01635-z"},{"key":"1816_CR50","doi-asserted-by":"crossref","unstructured":"Yan YY, Guo QR, Wang FH, Adhikari R, Zhu ZY, Zhang HY, et al. Cell-free DNA: Hope and potential application in cancer. Front Cell Dev Biol [Internet]. Frontiers Media S.A.; 2021 [cited 2025 Oct 12];9:639233.","DOI":"10.3389\/fcell.2021.639233"},{"key":"1816_CR51","doi-asserted-by":"publisher","unstructured":"Gaitsch H, Franklin RJM, Reich DS. Cell-free DNA-based liquid biopsies in neurology. Brain [Internet]. Oxford University Press; 2022 [cited 2025 Oct 12];146:1758. https:\/\/doi.org\/10.1093\/BRAIN\/AWAC438.","DOI":"10.1093\/BRAIN\/AWAC438"},{"key":"1816_CR52","doi-asserted-by":"publisher","unstructured":"Tivey A, Church M, Rothwell D, Dive C, Cook N. Circulating tumour DNA \u2014 looking beyond the blood. Nat Rev Clin Oncol [Internet]. Springer Nature; 2022 [cited 2025 Oct 12];19:600. https:\/\/doi.org\/10.1038\/S41571-022-00660-Y.","DOI":"10.1038\/S41571-022-00660-Y"},{"key":"1816_CR53","doi-asserted-by":"crossref","unstructured":"Peng H, Pan M, Zhou Z, Chen C, Xing X, Cheng S, et al. The impact of preanalytical variables on the analysis of cell-free DNA from blood and urine samples. Front Cell Dev Biol. Frontiers Media SA; 2024;12:1385041.","DOI":"10.3389\/fcell.2024.1385041"},{"key":"1816_CR54","doi-asserted-by":"publisher","unstructured":"Fang X, Yang Z, Zhou J, Chen X, Li P. Application of circulating tumor DNA analysis in detecting Minimal residual disease (MRD) after surgery for locally advanced head and neck squamous cell carcinoma: a preliminary study. Acta Otolaryngol [Internet]. Acta Otolaryngol; 2025 [cited 2025 Sep 27];1\u20136. https:\/\/doi.org\/10.1080\/00016489.2025.2561924.","DOI":"10.1080\/00016489.2025.2561924"},{"key":"1816_CR55","unstructured":"Successful readout of prospective phase 2 SINERGY trial supports signateraTM MRD-guided treatment in head and neck cancer | Natera [Internet]. [cited 2026 Apr 14]. https:\/\/www.natera.com\/company\/news\/successful-readout-of-prospective-phase-2-sinergy-trial-supports-signateratm-mrd-guided-treatment-in-head-and-neck-cancer\/. Accessed 14 Apr 2026."},{"key":"1816_CR56","doi-asserted-by":"publisher","unstructured":"Chen L, Cohen M, Hatzglou V, Zhang Z, Riaz N, Shamseddine AA, et al. Postoperative human papilloma virus circulating tumor DNA guided adjuvant therapy for human papilloma virus-related oropharyngeal carcinoma (PATH Study). Int J Radiat Oncol Biol Phys [Internet]. Int J Radiat Oncol Biol Phys; 2026 [cited 2026 Jul 26];124:676\u201385. https:\/\/doi.org\/10.1016\/J.IJROBP.2025.09.044.","DOI":"10.1016\/J.IJROBP.2025.09.044"},{"key":"1816_CR57","doi-asserted-by":"publisher","unstructured":"Brooks PJ, Bratman S V. Liquid biopsies in head and neck cancers: Recent developments across biofluids, analytes, and molecular features. Head Neck [Internet]. John Wiley & Sons, Ltd; 2025 [cited 2025 Oct 12];0:1\u201322. https:\/\/doi.org\/10.1002\/HED.70009.","DOI":"10.1002\/HED.70009"},{"key":"1816_CR58","doi-asserted-by":"publisher","unstructured":"Patel A, Patel S, Patel P, Tanavde V. Saliva based liquid biopsies in head and neck cancer: How far are we from the clinic? Front Oncol [Internet]. Frontiers Media S.A.; 2022 [cited 2025 Oct 12];12:828434. https:\/\/doi.org\/10.3389\/FONC.2022.828434.","DOI":"10.3389\/FONC.2022.828434"},{"key":"1816_CR59","doi-asserted-by":"publisher","unstructured":"Earland N, Semenkovich NP, Ramirez RJ, Gerndt SP, Harris PK, Gu Z, et al. Sensitive MRD detection from lymphatic fluid after surgery in HPV-associated oropharyngeal cancer. Clin Cancer Res [Internet]. Clin Cancer Res; 2024 [cited 2025 Sep 28];30:1409\u201321. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1789.","DOI":"10.1158\/1078-0432.CCR-23-1789"},{"key":"1816_CR60","doi-asserted-by":"publisher","unstructured":"Helou V, Smith JD, Harris M, Earland N, Contrera KJ, Chaudhuri AA, et al. Emerging proximal liquid biopsy approaches for detecting residual disease and predicting recurrence in head and neck cancer: A review and proposal of novel liquid staging. Head Neck [Internet]. John Wiley and Sons Inc; 2025 [cited 2025 Oct 11];47:1779. https:\/\/doi.org\/10.1002\/HED.28138.","DOI":"10.1002\/HED.28138"},{"key":"1816_CR61","doi-asserted-by":"publisher","unstructured":"Mehanna H, Wong W-L, McConkey CC, Rahman JK, Robinson M, Hartley AGJ, et al. PET-CT surveillance versus neck dissection in advanced head and neck cancer. N Engl J Med [Internet]. N Engl J Med; 2016 [cited 2025 Sep 28];374:1444\u201354. https:\/\/doi.org\/10.1056\/NEJMOA1514493.","DOI":"10.1056\/NEJMOA1514493"},{"key":"1816_CR62","doi-asserted-by":"publisher","first-page":"106481","DOI":"10.1016\/J.ORALONCOLOGY.2023.106481","volume":"144","author":"SB Mali","year":"2023","unstructured":"Mali SB. Molecular screening of head neck cancer. Oral Oncol Pergamon. 2023;144:106481. https:\/\/doi.org\/10.1016\/J.ORALONCOLOGY.2023.106481.","journal-title":"Oral Oncol. Pergamon"},{"key":"1816_CR63","doi-asserted-by":"publisher","unstructured":"Dong Q, Chen C, Hu Y, Zhang W, Yang X, Qi Y, et al. Clinical application of molecular residual disease detection by circulation tumor DNA in solid cancers and a comparison of technologies: review article. Cancer Biol Ther [Internet]. Taylor & Francis; 2023 [cited 2025 Oct 12];24. https:\/\/doi.org\/10.1080\/15384047.2023.2274123.","DOI":"10.1080\/15384047.2023.2274123"},{"key":"1816_CR64","doi-asserted-by":"publisher","unstructured":"Riggauer J, Blaser D, Elicin O, Gahl B, Giger R, Mueller SA. Risk factors for fear of recurrence in head and neck cancer patients. Laryngoscope [Internet]. John Wiley & Sons, Ltd; 2023 [cited 2026 Jul 26];133:1630\u20137. https:\/\/doi.org\/10.1002\/LARY.30340.","DOI":"10.1002\/LARY.30340"},{"key":"1816_CR65","doi-asserted-by":"publisher","unstructured":"Allner M, Rak A, Balk M, Rupp R, Almajali O, Tamse H, et al. Patient-reported outcomes in head and neck cancer: a cross-sectional analysis of quality of life domains across early and advanced UICC stages. Support Care Cancer [Internet]. Support Care Cancer; 2025 [cited 2025 Oct 8];33. https:\/\/doi.org\/10.1007\/S00520-025-09204-3.","DOI":"10.1007\/S00520-025-09204-3"},{"key":"1816_CR66","doi-asserted-by":"publisher","unstructured":"Cescon DW, Kalinsky K, Parsons HA, Smith KL, Spears PA, Thomas A, et al. Therapeutic targeting of minimal residual disease to prevent late recurrence in hormone-receptor positive breast cancer: Challenges and new approaches. Front Oncol [Internet]. Frontiers Media S.A.; 2022 [cited 2025 Sep 28];11:667397. https:\/\/doi.org\/10.3389\/FONC.2021.667397.","DOI":"10.3389\/FONC.2021.667397"},{"key":"1816_CR67","doi-asserted-by":"publisher","unstructured":"Landgren O, Prior TJ, Masterson T, Heuck C, Bueno OF, Dash AB, et al. EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma. Blood. Content Repository Only!; 2024;144:359\u201367. https:\/\/doi.org\/10.1182\/BLOOD.2024024371.","DOI":"10.1182\/BLOOD.2024024371"},{"key":"1816_CR68","doi-asserted-by":"publisher","unstructured":"Correia N, Dowling E, Popat R, Rabin N, Kyriakou C, Sive J, et al. Functional and psychological impact of minimal residual disease assessment on patients with multiple myeloma. Br J Haematol [Internet]. John Wiley & Sons, Ltd; 2023 [cited 2025 Sep 28];202:e43\u20135. https:\/\/doi.org\/10.1111\/BJH.18948.","DOI":"10.1111\/BJH.18948"},{"key":"1816_CR69","doi-asserted-by":"publisher","unstructured":"Wangaryattawanich P, Anzai Y, Mead-Harvey C, Almader-Douglas D, Rath TJ. Does long-term surveillance imaging improve survival in patients treated for head and neck squamous cell carcinoma? A systematic review of the current evidence. Am J Neuroradiol [Internet]. American Journal of Neuroradiology; 2025 [cited 2026 Jul 26];46:153\u20139. https:\/\/doi.org\/10.3174\/AJNR.A8392.","DOI":"10.3174\/AJNR.A8392"},{"key":"1816_CR70","doi-asserted-by":"crossref","unstructured":"Anzai Y, Chang CP, Rowe K, Snyder J, Deshmukh V, Newman M, et al. Surveillance imaging with PET\/CT and CT and\/or MRI for head and neck cancer and mortality: A population-based study. Radiology [Internet]. Radiological Society of North America Inc.; 2023 [cited 2026 Jul 26];307.","DOI":"10.1148\/radiol.212915"},{"key":"1816_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1148\/RADIOL.230286","volume":"308","author":"MF Gensheimer","year":"2023","unstructured":"Gensheimer MF. Potential biases in a population-based study of surveillance imaging for head and neck cancer. Radiol Soc North Am. 2023;308:1\u20132. https:\/\/doi.org\/10.1148\/RADIOL.230286.","journal-title":"Radiol Soc North Am"},{"key":"1816_CR72","doi-asserted-by":"crossref","unstructured":"Nijhuis AAG, Dieng M, Khanna N, Lord SJ, Dalton J, Menzies AM, et al. False-positive results and incidental findings with annual CT or PET\/CT surveillance in asymptomatic patients with resected stage III Melanoma. Ann Surg Oncol [Internet]. Springer Science and Business Media Deutschland GmbH; 2019 [cited 2026 Jul 26];26:1860\u20138.","DOI":"10.1245\/s10434-019-07311-0"},{"key":"1816_CR73","doi-asserted-by":"publisher","unstructured":"Konerman MA, Verma A, Zhao B, Singal AG, Lok AS, Parikh ND. Frequency and outcomes of abnormal imaging in patients with cirrhosis enrolled in a hepatocellular carcinoma surveillance program. Liver Transpl [Internet]. Liver Transpl; 2019 [cited 2026 Jul 26];25:369\u201379. https:\/\/doi.org\/10.1002\/LT.25398.","DOI":"10.1002\/LT.25398"},{"key":"1816_CR74","doi-asserted-by":"publisher","unstructured":"Ganguli I, Simpkin AL, Lupo C, Weissman A, Mainor AJ, Orav EJ, et al. Cascades of care after incidental findings in a US National survey of physicians. JAMA Netw Open [Internet]. American Medical Association; 2019 [cited 2026 Jul 26];2:e1913325. https:\/\/doi.org\/10.1001\/JAMANETWORKOPEN.2019.13325.","DOI":"10.1001\/JAMANETWORKOPEN.2019.13325"},{"key":"1816_CR75","doi-asserted-by":"publisher","unstructured":"Ruiz-Torres DA, Merkin RD, Bryan ME, Mendel J, Efthymiou V, Roberts T, et al. Personalized circulating tumor DNA dynamics inform survival and response to immune checkpoint blockade in recurrent\/metastatic head and neck cancer. npj Precis Oncol [Internet]. Nature Publishing Group; 2025 [cited 2025 Oct 11];9(1):1\u20139. https:\/\/doi.org\/10.1038\/s41698-025-01084-4.","DOI":"10.1038\/s41698-025-01084-4"},{"key":"1816_CR76","doi-asserted-by":"publisher","unstructured":"Jang A, Jaeger EB, Rauterkus G, Lieberman A, Huang M, Lanka SM, et al. Utility of circulating tumor DNA in monitoring treatment response to immune checkpoint inhibitors in patients with advanced genitourinary cancers. J Clin Oncol [Internet]. American Society of Clinical Oncology; 2023 [cited 2025 Oct 12];41:721\u2013721. https:\/\/doi.org\/10.1200\/JCO.2023.41.6_SUPPL.721.","DOI":"10.1200\/JCO.2023.41.6_SUPPL.721"},{"key":"1816_CR77","doi-asserted-by":"publisher","unstructured":"Noji R, Tohyama K, Nakamura S, Naito T, Oikawa Y, Kuroshima T, et al. Dynamic changes in circulating tumor DNA during immunotherapy for head and neck cancer: SHIZUKU-HN study. Int J Mol Sci [Internet]. Multidisciplinary Digital Publishing Institute (MDPI); 2024 [cited 2025 Oct 12];26:235. https:\/\/doi.org\/10.3390\/IJMS26010235.","DOI":"10.3390\/IJMS26010235"},{"key":"1816_CR78","doi-asserted-by":"publisher","unstructured":"Nakamura Y, Ozaki H, Ueno M, Komatsu Y, Yuki S, Esaki T, et al. Targeted therapy guided by circulating tumor DNA analysis in advanced gastrointestinal tumors. Nat Med [Internet]. Nature Publishing Group; 2024 [cited 2025 Oct 12];31(1):165\u201375. https:\/\/doi.org\/10.1038\/s41591-024-03244-8.","DOI":"10.1038\/s41591-024-03244-8"},{"key":"1816_CR79","doi-asserted-by":"publisher","unstructured":"Huisman C, Rozendal P, Schuuring E, Hiltermann TJN. Emerging role of circulating tumor DNA as a predictive biomarker in consolidation immunotherapy for unresectable stage III NSCLC. AME Clin Trials Rev [Internet]. AME Publishing Company; 2025 [cited 2025 Oct 12];3:15\u201315. https:\/\/doi.org\/10.21037\/ACTR-24-201.","DOI":"10.21037\/ACTR-24-201"},{"key":"1816_CR80","doi-asserted-by":"publisher","unstructured":"Asnaghi R, Marsicano RM, Fuorivia V, Malvezzi G, Etessami JD, Izzo D, et al. Circulating tumor DNA: a biomarker for oncology drug development in phase I clinical trials? Expert Rev Mol Diagn [Internet]. Taylor & Francis; 2025 [cited 2025 Oct 12]; https:\/\/doi.org\/10.1080\/14737159.2025.2531065.","DOI":"10.1080\/14737159.2025.2531065"},{"key":"1816_CR81","doi-asserted-by":"publisher","unstructured":"Bartolomucci A, Nobrega M, Ferrier T, Dickinson K, Kaorey N, Nadeau A, et al. Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology. npj Precis Oncol [Internet]. Nature Publishing Group; 2025 [cited 2025 Sep 27];9(1):1\u201319. https:\/\/doi.org\/10.1038\/s41698-025-00876-y.","DOI":"10.1038\/s41698-025-00876-y"},{"key":"1816_CR82","doi-asserted-by":"crossref","unstructured":"Li A, Lou E, Leder K, Foo J. Early circulating tumor DNA kinetics as a dynamic biomarker of cancer treatment response. JCO Clin Cancer Inform [Internet]. American Society of Clinical Oncology (ASCO); 2025 [cited 2025 Oct 11].","DOI":"10.1200\/CCI-24-00160"},{"key":"1816_CR83","doi-asserted-by":"publisher","unstructured":"Chandhok NS, Sekeres MA. Measurable residual disease in hematologic malignancies: a biomarker in search of a standard. EClinicalMedicine [Internet]. Elsevier; 2025 [cited 2025 Sep 28];86. https:\/\/doi.org\/10.1016\/J.ECLINM.2025.103348.","DOI":"10.1016\/J.ECLINM.2025.103348"},{"key":"1816_CR84","doi-asserted-by":"publisher","unstructured":"Song M, Pan W, Yu X, Ren J, Tang C, Chen Z, et al. Minimal residual disease detection: Implications for clinical diagnosis and cancer patient treatment. MedComm (Beijing) [Internet]. John Wiley and Sons Inc; 2025 [cited 2025 Sep 28];6:e70193. https:\/\/doi.org\/10.1002\/MCO2.70193.","DOI":"10.1002\/MCO2.70193"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01816-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-026-01816-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01816-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T06:09:08Z","timestamp":1787551748000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-026-01816-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":84,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1816"],"URL":"https:\/\/doi.org\/10.1007\/s11912-026-01816-0","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"assertion":[{"value":"14 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This review did\u00a0not involve human participants, patient\u00a0data, or animal subjects. All\u00a0information presented was obtained\u00a0from previously published,\u00a0peer-reviewed literature. Institutional\u00a0review board approval and informed\u00a0consent were not required.","order":1,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors\u00a0have no relevant\u00a0financial or non-financial interests to\u00a0disclose.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"85"}}